November 21, 2022

To,
The Secretary
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code - 532523

To,
The Secretary
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Symbol - BIOCON

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

Dear Sir/ Madam,

In reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited (“BBL”), subsidiary of Biocon Limited, please be informed that BBL and its subsidiaries have executed a Debt Facility Agreement which is classified as a Sustainability-linked Loan (SLL) amounting to US$1.2 billion on November 20, 2022, the proceeds of which shall be used for funding the acquisition of Viatris Inc.’s biosimilars business and acquisition related expenses.

We request you to take this on record.

Thanking You,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776